

Neal L Benowitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8158694/publications.pdf>

Version: 2024-02-01

364
papers

34,007
citations

3933

88
h-index

4432

172
g-index

368
all docs

368
docs citations

368
times ranked

20748
citing authors

#	ARTICLE	IF	CITATIONS
1	Nicotine delivery and cigarette equivalents from vaping a JUULpod. Tobacco Control, 2022, 31, e88-e93.	3.2	60
2	Correlates of the nicotine metabolite ratio in Alaska Native people who smoke cigarettes.. Experimental and Clinical Psychopharmacology, 2022, 30, 359-364.	1.8	2
3	Reappraising Choice in Addiction: Novel Conceptualizations and Treatments for Tobacco Use Disorder. Nicotine and Tobacco Research, 2022, 24, 3-9.	2.6	14
4	Tobacco use disorder and cardiovascular health. Addiction, 2022, 117, 1128-1138.	3.3	23
5	Functional characterization of novel rare <i>CYP2A6</i> variants and potential implications for clinical outcomes. Clinical and Translational Science, 2022, 15, 204-220.	3.1	8
6	Determination of 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone (NNK) arising from tobacco smoke in airborne particulate matter. Environment International, 2022, 158, 106992.	10.0	2
7	Does sex alter the relationship between <i>CYP2B6</i> variation, hydroxybupropion concentration and bupropionâ€aided smoking cessation in African Americans? A moderated mediation analysis. Addiction, 2022, 117, 1715-1724.	3.3	3
8	Relations among cigarette dependence, e-cigarette dependence, and key dependence criteria among dual users of combustible and e-cigarettes.. Psychology of Addictive Behaviors, 2022, 36, 100-108.	2.1	5
9	Cigarette Smoke Exposure and Acute Respiratory Distress Syndrome in Sepsis: Epidemiology, Clinical Features, and Biologic Markers. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 927-935.	5.6	9
10	Balfour etÂal. Respond. American Journal of Public Health, 2022, 112, e2-e3.	2.7	1
11	Balfour etÂal. Respond. American Journal of Public Health, 2022, 112, e5-e6.	2.7	0
12	Effects of Marijuana Use on Smokers Switching to E-Cigarettes in a Randomized Clinical Trial. Nicotine and Tobacco Research, 2022, 24, 994-1002.	2.6	6
13	Associations of Smokeless Tobacco Use With Cardiovascular Disease Risk: Insights From the Population Assessment of Tobacco and Health Study. Nicotine and Tobacco Research, 2022, 24, 1063-1070.	2.6	3
14	Nicotine Addiction and Its Treatment. , 2022, , 297-341.		0
15	Exposure to Toxicants Associated With Use and Transitions Between Cigarettes, e-Cigarettes, and No Tobacco. JAMA Network Open, 2022, 5, e2147891.	5.9	22
16	Tobacco-specific and combustion pollutants in settled house dust in Malta. , 2022, 1, .		2
17	The Central Role of pH in the Clinical Pharmacology of Nicotine: Implications for Abuse Liability, Cigarette Harm Reduction and FDA Regulation. Clinical Pharmacology and Therapeutics, 2022, 111, 1004-1006.	4.7	10
18	Maternal nicotine metabolism moderates the impact of maternal cigarette smoking on infant birth weight: A Collaborative Perinatal Project investigation. Drug and Alcohol Dependence, 2022, 233, 109358.	3.2	2

#	ARTICLE	IF	CITATIONS
19	Early Changes in Puffing Intensity When Exclusively Using Open-Label Very Low Nicotine Content Cigarettes. <i>Nicotine and Tobacco Research</i> , 2022, , .	2.6	1
20	Minor Tobacco Alkaloids as Biomarkers to Distinguish Combusted Tobacco Use From Electronic Nicotine Delivery Systems Use. Two New Analytical Methods. <i>Frontiers in Chemistry</i> , 2022, 10, .	3.6	1
21	Effect of Varenicline Added to Counseling on Smoking Cessation Among African American Daily Smokers. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 2201.	7.4	9
22	Australian smokersâ€™ experiences and perceptions of recessed and firm filter cigarettes. <i>Tobacco Control</i> , 2021, 30, 660-667.	3.2	4
23	Efficacy and Safety of Pharmacotherapeutic Smoking Cessation Aids in Schizophrenia Spectrum Disorders: Subgroup Analysis of EAGLES. <i>Psychiatric Services</i> , 2021, 72, 7-15.	2.0	25
24	Transferability of Ancestryâ€™Specific and Crossâ€™Ancestry CYP2A6 Activity Genetic Risk Scores in African and European Populations. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 975-985.	4.7	15
25	Differences in exposure to toxic and/or carcinogenic volatile organic compounds between Black and White cigarette smokers. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 2021, 31, 211-223.	3.9	14
26	Evidence of the effectiveness and safety of first-line smoking cessation pharmacotherapy. , 2021, , 97-117.		3
27	E-Cigarettes and Cardiopulmonary Health. <i>Function</i> , 2021, 2, zqab004.	2.3	36
28	Effect of race and glucuronidation rates on the relationship between nicotine metabolite ratio and nicotine clearance. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 97-107.	1.5	6
29	A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial). <i>Nicotine and Tobacco Research</i> , 2021, 23, 1656-1663.	2.6	16
30	Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors. <i>Addiction</i> , 2021, 116, 2816-2824.	3.3	7
31	Ubiquitous atmospheric contamination by tobacco smoke: Nicotine and a new marker for tobacco smoke-derived particulate matter, nicotelline. <i>Environment International</i> , 2021, 150, 106417.	10.0	20
32	3-Ethenylpyridine Measured in Urine of Active and Passive Smokers: A Promising Biomarker and Toxicological Implications. <i>Chemical Research in Toxicology</i> , 2021, 34, 1630-1639.	3.3	4
33	Nicotine metabolite ratio: Comparison of the three urinary versions to the plasma version and nicotine clearance in three clinical studies. <i>Drug and Alcohol Dependence</i> , 2021, 223, 108708.	3.2	7
34	A mixed effects model for analyzing area under the curve of longitudinally measured biomarkers with missing data. <i>Pharmaceutical Statistics</i> , 2021, 20, 1249-1264.	1.3	0
35	Thirdhand smoke associations with the gut microbiomes of infants admitted to a neonatal intensive care unit: An observational study. <i>Environmental Research</i> , 2021, 197, 111180.	7.5	15
36	Clinical Pharmacology of Electronic Nicotine Delivery Systems (ENDS): Implications for Benefits and Risks in the Promotion of the Combusted Tobacco Endgame. <i>Journal of Clinical Pharmacology</i> , 2021, 61, S18-S36.	2.0	17

#	ARTICLE	IF	CITATIONS
37	Balancing Consideration of the Risks and Benefits of E-Cigarettes. American Journal of Public Health, 2021, 111, 1661-1672.	2.7	150
38	Analyses of nicotine metabolism biomarker genetics stratified by sex in African and European Americans. Scientific Reports, 2021, 11, 19572.	3.3	8
39	Neurobiology of Nicotine and Tobacco. , 2021, , .		2
40	Assessment of Racial Differences in Pharmacotherapy Efficacy for Smoking Cessation. JAMA Network Open, 2021, 4, e2032053.	5.9	25
41	“I actually finally feel like the cigarettes aren’t controlling me.” Interviews with participants smoking very low nicotine content cigarettes during a residential study. Drug and Alcohol Dependence, 2021, 219, 108465.	3.2	11
42	Secondhand smoke exposure in school children in Malta assessed through urinary biomarkers. Environmental Research, 2021, 204, 112405.	7.5	0
43	Tobacco-free Nicotine “New Name, Same Scheme?. New England Journal of Medicine, 2021, 385, 2406-2408.	27.0	15
44	Changes in Use Patterns Over 1 Year Among Smokers and Dual Users of Combustible and Electronic Cigarettes. Nicotine and Tobacco Research, 2020, 22, 672-680.	2.6	53
45	E-cigarette Dependence Measures in Dual Users: Reliability and Relations With Dependence Criteria and E-cigarette Cessation. Nicotine and Tobacco Research, 2020, 22, 756-763.	2.6	55
46	Urine Metabolites for Estimating Daily Intake of Nicotine From Cigarette Smoking. Nicotine and Tobacco Research, 2020, 22, 288-292.	2.6	33
47	Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity. Addiction Biology, 2020, 25, e12741.	2.6	25
48	Impact of early nausea on varenicline adherence and smoking cessation. Addiction, 2020, 115, 134-144.	3.3	14
49	Biochemical Verification of Tobacco Use and Abstinence: 2019 Update. Nicotine and Tobacco Research, 2020, 22, 1086-1097.	2.6	325
50	Development and Piloting Testing of an Experimental Tobacco and Nicotine Product Marketplace. Nicotine and Tobacco Research, 2020, 22, 1230-1234.	2.6	4
51	Biomarkers of Exposure to Nicotine and Tobacco-Specific Nitrosamines in Adolescent Blunt Users. Nicotine and Tobacco Research, 2020, 22, 1428-1429.	2.6	3
52	Exposure to a Tobacco-Specific Carcinogen Among Adolescent Smokeless Tobacco Users in Rural California, United States. Nicotine and Tobacco Research, 2020, 22, 1764-1771.	2.6	2
53	Reductions in urinary metabolites of exposure to household air pollution in pregnant, rural Guatemalan women provided liquefied petroleum gas stoves. Journal of Exposure Science and Environmental Epidemiology, 2020, 30, 362-373.	3.9	7
54	Differences in nicotine intake and effects from electronic and combustible cigarettes among dual users. Addiction, 2020, 115, 757-767.	3.3	31

#	ARTICLE	IF	CITATIONS
55	Comparison of Systemic Exposure to Toxic and/or Carcinogenic Volatile Organic Compounds (VOC) during Vaping, Smoking, and Abstinence. <i>Cancer Prevention Research</i> , 2020, 13, 153-162.	1.5	54
56	Sources and Biomarkers of Secondhand Tobacco Smoke Exposure in Urban Adolescents. <i>Academic Pediatrics</i> , 2020, 20, 493-500.	2.0	11
57	Seizures After Vaping Nicotine in Youth: A Canary or a Red Herring?. <i>Journal of Adolescent Health</i> , 2020, 66, 1-2.	2.5	9
58	E-cigarettes and dual nicotine replacement therapy for smoking cessation. <i>Lancet Respiratory Medicine</i> , 2020, 8, 7-8.	10.7	5
59	Characterization of Nicotine Salts in 23 Electronic Cigarette Refill Liquids. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1239-1243.	2.6	85
60	Biomarkers of Exposure for Dual Use of Electronic Cigarettes and Combustible Cigarettes: Nicotelline, NNAL, and Total Nicotine Equivalents. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1107-1113.	2.6	17
61	Twenty-four-hour subjective and pharmacological effects of ad libitum electronic and combustible cigarette use among dual users. <i>Addiction</i> , 2020, 115, 1149-1159.	3.3	13
62	The influence of nicotine metabolic rate on working memory over 6 hours of abstinence from nicotine. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 188, 172836.	2.9	2
63	Effects of Nicotine Metabolic Rate on Cigarette Reinforcement. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1419-1423.	2.6	3
64	Effect of e-cigarette flavors on nicotine delivery and puffing topography: results from a randomized clinical trial of daily smokers. <i>Psychopharmacology</i> , 2020, 237, 491-502.	3.1	37
65	Relationships Between Race, Gender, and Spot Urine Levels of Biomarkers of Tobacco Exposure Vary Based on How Creatinine Is Handled in Analyses. <i>Nicotine and Tobacco Research</i> , 2020, 22, 2109-2113.	2.6	5
66	Effect of Pod e-Cigarettes vs Cigarettes on Carcinogen Exposure Among African American and Latinx Smokers. <i>JAMA Network Open</i> , 2020, 3, e2026324.	5.9	55
67	Twenty-Four-Hour Cardiovascular Effects of Electronic Cigarettes Compared With Cigarette Smoking in Dual Users. <i>Journal of the American Heart Association</i> , 2020, 9, e017317.	3.7	14
68	Recruitment best practices of a cardiovascular risk reduction randomised control trial in rural Alaska Native communities. <i>International Journal of Circumpolar Health</i> , 2020, 79, 1806639.	1.2	1
69	Mouth-Level Nicotine Intake Estimates from Discarded Filter Butts to Examine Compensatory Smoking in Low Nicotine Cigarettes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 643-649.	2.5	11
70	Comprehensive Parent-Metabolite PBPK/PD Modeling Insights into Nicotine Replacement Therapy Strategies. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1119-1134.	3.5	8
71	Comparison of smoking cessation rates of Quitline users in Korea between smokers of ultra-low nicotine yield cigarettes and other types of cigarette: a prospective study. <i>Addiction</i> , 2020, 115, 1745-1753.	3.3	2
72	Cigarette Smoking and ARDS After Blunt Trauma. <i>Chest</i> , 2020, 158, 1490-1498.	0.8	8

#	ARTICLE	IF	CITATIONS
73	Relationships between the Nicotine Metabolite Ratio and a Panel of Exposure and Effect Biomarkers: Findings from Two Studies of U.S. Commercial Cigarette Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 871-879.	2.5	17
74	Peripheral Blood Flow Changes to Cutaneous and Muscular Beds in Response to Acute Hookah Smoking. <i>American Journal of Cardiology</i> , 2020, 125, 1725-1731.	1.6	5
75	Evaluation of nicotine patch adherence measurement using self-report and saliva cotinine among abstainers in a smoking cessation trial. <i>Drug and Alcohol Dependence</i> , 2020, 210, 107967.	3.2	1
76	The Impact of Exclusive Use of Very Low Nicotine Cigarettes on Compensatory Smoking: An Inpatient Crossover Clinical Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 880-886.	2.5	20
77	Cultural and demographic correlates of dual tobacco use in a sample of Alaska Native adults who smoke cigarettes. <i>Tobacco Induced Diseases</i> , 2020, 18, 55.	0.6	4
78	A Mobile Health Intervention for Adolescents Exposed to Secondhand Smoke: Pilot Feasibility and Efficacy Study. <i>JMIR Formative Research</i> , 2020, 4, e18583.	1.4	1
79	Relations among cigarette dependence, e-cigarette dependence, and key dependence criteria among dual users of combustible and e-cigarettes. <i>Psychology of Addictive Behaviors</i> , 2020, , .	2.1	1
80	Stimulant drugs are associated with violent and penetrating trauma. <i>American Journal of Emergency Medicine</i> , 2019, 37, 645-650.	1.6	2
81	JUUL electronic cigarettes: Nicotine exposure and the user experience. <i>Drug and Alcohol Dependence</i> , 2019, 203, 83-87.	3.2	42
82	Black Light Smokers: How Nicotine Intake and Carcinogen Exposure Differ Across Various Biobehavioral Factors. <i>Journal of the National Medical Association</i> , 2019, 111, 509-520.	0.8	7
83	Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. <i>Addiction</i> , 2019, 114, 1951-1969.	3.3	63
84	Current advances in research in treatment and recovery: Nicotine addiction. <i>Science Advances</i> , 2019, 5, eaay9763.	10.3	112
85	Quantitative biochemical screening for marijuana use and concordance with tobacco use in urban adolescents. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107583.	3.2	13
86	E-Hookah Versus E-Cigarettes: Findings From Wave 2 of the PATH Study (2014â€“2015). <i>American Journal of Preventive Medicine</i> , 2019, 57, e163-e173.	3.0	12
87	Nicotine Intake, Dependence, and Characteristics of Electronic Cigarette and Dual Users. <i>Tobacco Regulatory Science (discontinued)</i> , 2019, 5, 27-35.	0.2	12
88	Relationship between skin melanin index and nicotine pharmacokinetics in African American smokers. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107474.	3.2	5
89	Factors That Explain Differences in Abstinence Between Black and White Smokers: A Prospective Intervention Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1078-1087.	6.3	52
90	Effects of immediate versus gradual nicotine reduction in cigarettes on biomarkers of biological effects. <i>Addiction</i> , 2019, 114, 1824-1833.	3.3	4

#	ARTICLE	IF	CITATIONS
91	Longitudinal stability in cigarette smokers of urinary eicosanoid biomarkers of oxidative damage and inflammation. PLoS ONE, 2019, 14, e0215853.	2.5	10
92	Predictors of Neuropsychiatric Adverse Events with Smoking Cessation Medications in the Randomized Controlled EAGLES Trial. Journal of General Internal Medicine, 2019, 34, 862-870.	2.6	15
93	Randomized within-subject trial to evaluate smokers' initial perceptions, subjective effects and nicotine delivery across six vaporized nicotine products. Addiction, 2019, 114, 1236-1248.	3.3	26
94	Loperamide associated torsades de pointes, in the setting of complete heart block at marginally supratherapeutic dosing (20mg/day). Clinical Toxicology, 2019, 57, 1123-1124.	1.9	2
95	High Carbon Monoxide Levels from Charcoal Combustion Mask Acute Endothelial Dysfunction Induced by Hookah (Waterpipe) Smoking in Young Adults. Circulation, 2019, 139, 2215-2224.	1.6	19
96	Managing Cannabis Use in Patients With Cardiovascular Disease. Canadian Journal of Cardiology, 2019, 35, 138-141.	1.7	6
97	Effects of Very Low Nicotine Content Cigarettes on Smoking Behavior and Biomarkers of Exposure in Menthol and Non-menthol Smokers. Nicotine and Tobacco Research, 2019, 21, S63-S72.	2.6	17
98	The Role of Compensation in Nicotine Reduction. Nicotine and Tobacco Research, 2019, 21, S16-S18.	2.6	17
99	Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers With Psychotic, Anxiety, and Mood Disorders in the EAGLES Trial. Journal of Clinical Psychopharmacology, 2019, 39, 108-116.	1.4	67
100	Electronic cigarette chemicals transfer from a vape shop to a nearby business in a multiple-tenant retail building. Tobacco Control, 2019, 28, 519-525.	3.2	27
101	Identification and quantification of electronic cigarette exhaled aerosol residue chemicals in field sites. Environmental Research, 2019, 170, 351-358.	7.5	15
102	Butanediol Conversion to Gamma-Hydroxybutyrate Markedly Reduced by the Alcohol Dehydrogenase Blocker Fomepizole. Clinical Pharmacology and Therapeutics, 2019, 105, 1196-1203.	4.7	7
103	Longitudinal stability in cigarette smokers of urinary biomarkers of exposure to the toxicants acrylonitrile and acrolein. PLoS ONE, 2019, 14, e0210104.	2.5	20
104	Biomarker feedback intervention for smoking cessation among Alaska Native pregnant women: Randomized pilot study. Patient Education and Counseling, 2019, 102, 528-535.	2.2	13
105	Dual Users Compared to Smokers: Demographics, Dependence, and Biomarkers. Nicotine and Tobacco Research, 2019, 21, 1279-1284.	2.6	58
106	Effects of Nicotine Metabolic Rate on Withdrawal Symptoms and Response to Cigarette Smoking After Abstinence. Clinical Pharmacology and Therapeutics, 2019, 105, 641-651.	4.7	28
107	Cardiovascular Effects of Hookah Smoking: Potential Implications for Cardiovascular Risk. Nicotine and Tobacco Research, 2019, 21, 1151-1161.	2.6	47
108	Evaluating the temporal relationships between withdrawal symptoms and smoking relapse.. Psychology of Addictive Behaviors, 2019, 33, 105-116.	2.1	45

#	ARTICLE	IF	CITATIONS
109	Tobacco Consumption and Toxicant Exposure of Cigarette Smokers Using Electronic Cigarettes. <i>Nicotine and Tobacco Research</i> , 2018, 20, ntw333.	2.6	54
110	Adolescent Exposure to Toxic Volatile Organic Chemicals From E-Cigarettes. <i>Pediatrics</i> , 2018, 141, .	2.1	129
111	Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES. <i>Addiction</i> , 2018, 113, 1507-1516.	3.3	58
112	Comparison of Urine 4-(Methylnitrosamino)-1-(3)Pyridyl-1-Butanol and Cotinine for Assessment of Active and Passive Smoke Exposure in Urban Adolescents. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 254-261.	2.5	41
113	Whether to push or pull? Nicotine reduction and non-combusted alternatives - Two strategies for reducing smoking and improving public health. <i>Preventive Medicine</i> , 2018, 117, 8-14.	3.4	30
114	Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers. <i>JAMA Internal Medicine</i> , 2018, 178, 622.	5.1	108
115	Short-term early exposure to thirdhand cigarette smoke increases lung cancer incidence in mice. <i>Clinical Science</i> , 2018, 132, 475-488.	4.3	30
116	Slower nicotine metabolism among postmenopausal Polish smokers. <i>Pharmacological Reports</i> , 2018, 70, 434-438.	3.3	7
117	Perceived risks and reasons to smoke cigarettes during pregnancy among Alaska native women. <i>Ethnicity and Health</i> , 2018, 23, 33-42.	2.5	6
118	Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences. <i>Addiction</i> , 2018, 113, 509-523.	3.3	45
119	Association of Reduced Nicotine Content Cigarettes With Smoking Behaviors and Biomarkers of Exposure Among Slow and Fast Nicotine Metabolizers. <i>JAMA Network Open</i> , 2018, 1, e181346.	5.9	20
120	2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3332-3365.	2.8	219
121	Reprint of: Prevention and Treatment of Tobacco Use. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2964-2979.	2.8	18
122	Effect of Î³-hydroxybutyrate (GHB) on driving as measured by a driving simulator. <i>Psychopharmacology</i> , 2018, 235, 3223-3232.	3.1	15
123	Urine 4-(methylnitrosamino)-1-(3) pyridyl-1-butanol and cotinine in Alaska native postpartum women and neonates comparing smokers and smokeless tobacco users. <i>International Journal of Circumpolar Health</i> , 2018, 77, 1528125.	1.2	7
124	Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 880.	7.4	113
125	IQOS: examination of Philip Morris International's claim of reduced exposure. <i>Tobacco Control</i> , 2018, 27, s30-s36.	3.2	135
126	The Healing and Empowering Alaskan Lives Toward Healthy-Hearts (HEALTHH) Project: Study protocol for a randomized controlled trial of an intervention for tobacco use and other cardiovascular risk behaviors for Alaska Native People. <i>Contemporary Clinical Trials</i> , 2018, 71, 40-46.	1.8	13

#	ARTICLE	IF	CITATIONS
127	Nicotine Reduction Strategy: State of the science and challenges to tobacco control policy and FDA tobacco product regulation. Preventive Medicine, 2018, 117, 5-7.	3.4	14
128	Another Article About E-cigarettes: Why Should I Care?. Journal of the American Heart Association, 2018, 7, .	3.7	4
129	Prevention and Treatment of Tobacco Use. Journal of the American College of Cardiology, 2018, 72, 1030-1045.	2.8	56
130	Collaborative Method Performance Study of the Measurement of Nicotine, Its Metabolites, and Total Nicotine Equivalents in Human Urine. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1083-1090.	2.5	15
131	Impact of e-liquid flavors on e-cigarette vaping behavior. Drug and Alcohol Dependence, 2018, 189, 42-48.	3.2	53
132	Secondhand smoke exposure and asthma outcomes among African-American and Latino children with asthma. Thorax, 2018, 73, 1041-1048.	5.6	30
133	Effects of reduced nicotine content cigarettes on individual withdrawal symptoms over time and during abstinence.. Experimental and Clinical Psychopharmacology, 2018, 26, 223-232.	1.8	10
134	Urine Cotinine Screening Detect Nearly Ubiquitous Tobacco Smoke Exposure in Urban Adolescents. Nicotine and Tobacco Research, 2017, 19, ntw390.	2.6	26
135	An Electronic Cigarette Vaping Machine for the Characterization of Aerosol Delivery and Composition. Nicotine and Tobacco Research, 2017, 19, ntw147.	2.6	36
136	Reduced nicotine content cigarettes, e-cigarettes and the cigarette end game. Addiction, 2017, 112, 6-7.	3.3	41
137	Early exposure to thirdhand cigarette smoke affects body mass and the development of immunity in mice. Scientific Reports, 2017, 7, 41915.	3.3	30
138	Thirdhand Smoke: New Evidence, Challenges, and Future Directions. Chemical Research in Toxicology, 2017, 30, 270-294.	3.3	178
139	Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma. Journal of the National Cancer Institute, 2017, 109, .	6.3	79
140	Nicotine biomarkers and rate of nicotine metabolism among cigarette smokers taking buprenorphine for opioid dependency. Drug and Alcohol Dependence, 2017, 178, 267-270.	3.2	7
141	Reducing nicotine exposure results in weight gain in smokers randomised to very low nicotine content cigarettes. Tobacco Control, 2017, 26, e43-e48.	3.2	17
142	Biomarkers of exposure to new and emerging tobacco delivery products. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L425-L452.	2.9	95
143	Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans. Pharmacogenetics and Genomics, 2017, 27, 143-154.	1.5	18
144	Cardiovascular effects of electronic cigarettes. Nature Reviews Cardiology, 2017, 14, 447-456.	13.7	197

#	ARTICLE	IF	CITATIONS
145	Exposure to polycyclic aromatic hydrocarbons and volatile organic compounds among recently pregnant rural Guatemalan women cooking and heating with solid fuels. <i>International Journal of Hygiene and Environmental Health</i> , 2017, 220, 726-735.	4.3	42
146	Tobacco toxicant exposure in cigarette smokers who use or do not use other tobacco products. <i>Drug and Alcohol Dependence</i> , 2017, 179, 330-336.	3.2	5
147	Urinary NNAL in hookah smokers and non-smokers after attending a hookah social event in a hookah lounge or a private home. <i>Regulatory Toxicology and Pharmacology</i> , 2017, 89, 74-82.	2.7	4
148	Measures and predictors of varenicline adherence in the treatment of nicotine dependence. <i>Addictive Behaviors</i> , 2017, 75, 122-129.	3.0	31
149	Impact of e-liquid flavors on nicotine intake and pharmacology of e-cigarettes. <i>Drug and Alcohol Dependence</i> , 2017, 178, 391-398.	3.2	83
150	Emissions from Electronic Cigarettes: Assessing Vapers' Intake of Toxic Compounds, Secondhand Exposures, and the Associated Health Impacts. <i>Environmental Science & Technology</i> , 2017, 51, 9271-9279.	10.0	85
151	Exposure to Nicotine and Selected Toxicants in Cigarette Smokers Who Switched to Electronic Cigarettes: A Longitudinal Within-Subjects Observational Study. <i>Nicotine and Tobacco Research</i> , 2017, 19, 160-167.	2.6	234
152	Effects of 6-Week Use of Reduced-Nicotine Content Cigarettes in Smokers With and Without Elevated Depressive Symptoms. <i>Nicotine and Tobacco Research</i> , 2017, 19, 59-67.	2.6	49
153	Nicotine Replacement, Topography, and Smoking Phenotypes of E-cigarettes. <i>Tobacco Regulatory Science</i> (discontinued), 2016, 2, 352-362.	0.2	25
154	Nicotine Delivery and Vaping Behavior during <i>ad libitum</i> E-cigarette Access. <i>Tobacco Regulatory Science</i> (discontinued), 2016, 2, 363-376.	0.2	71
155	Nicotine and Anatabine Exposure from Very Low Nicotine Content Cigarettes. <i>Tobacco Regulatory Science</i> (discontinued), 2016, 2, 186-203.	0.2	29
156	"You have the right to protect your health": Perceptions of Secondhand Smoke and Exposure Mitigation Strategies in Low-Income Patients With Heart Disease, San Francisco, 2011-2012. <i>Preventing Chronic Disease</i> , 2016, 13, E116.	3.4	0
157	Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes. <i>Addiction</i> , 2016, 111, 2208-2216.	3.3	44
158	Thirdhand Smoke: State of the Science and a Call for Policy Expansion. <i>Public Health Reports</i> , 2016, 131, 233-238.	2.5	43
159	Acute Effect of Hookah Smoking on the Human Coronary Microcirculation. <i>American Journal of Cardiology</i> , 2016, 117, 1747-1754.	1.6	19
160	The Influence of Puff Characteristics, Nicotine Dependence, and Rate of Nicotine Metabolism on Daily Nicotine Exposure in African American Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 936-943.	2.5	23
161	Fetal Exposure to Carcinogens With Tobacco Use in Pregnancy: Phase 1 MAW Study Findings. <i>Nicotine and Tobacco Research</i> , 2016, 18, 2162-2168.	2.6	10
162	Cessation of alcohol consumption decreases rate of nicotine metabolism in male alcohol-dependent smokers. <i>Drug and Alcohol Dependence</i> , 2016, 163, 157-164.	3.2	24

#	ARTICLE	IF	CITATIONS
163	Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. <i>Lancet, The</i> , 2016, 387, 2507-2520.	13.7	929
164	E-cigarette use results in suppression of immune and inflammatory-response genes in nasal epithelial cells similar to cigarette smoke. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2016, 311, L135-L144.	2.9	187
165	Disposition kinetics and metabolism of nicotine and cotinine in African American smokers. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 340-350.	1.5	30
166	Racial differences in the relationship between rate of nicotine metabolism and nicotine intake from cigarette smoking. <i>Pharmacology Biochemistry and Behavior</i> , 2016, 148, 1-7.	2.9	51
167	A clinical trial to examine disparities in quitting between African-American and White adult smokers: Design, accrual, and baseline characteristics. <i>Contemporary Clinical Trials</i> , 2016, 47, 12-21.	1.8	15
168	Genome-Wide Association of the Laboratory-Based Nicotine Metabolite Ratio in Three Ancestries. <i>Nicotine and Tobacco Research</i> , 2016, 18, 1837-1844.	2.6	37
169	Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes. <i>Addiction</i> , 2016, 111, 535-544.	3.3	204
170	Thirdhand smoke contamination in hospital settings: assessing exposure risk for vulnerable paediatric patients: TableA1. <i>Tobacco Control</i> , 2016, 25, 619-623.	3.2	53
171	Minoxidil-Associated Pleuropericardial Effusion. <i>Journal of General Internal Medicine</i> , 2016, 31, 1105-1105.	2.6	7
172	Cardiovascular toxicity of nicotine: Implications for electronic cigarette use. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 515-523.	4.9	301
173	Nicotine Metabolite Ratio Is Associated With Lozenge Use But Not Quitting in Smokeless Tobacco Users. <i>Nicotine and Tobacco Research</i> , 2016, 18, 366-370.	2.6	6
174	The Past, Present, and Future of Nicotine Addiction Therapy. <i>Annual Review of Medicine</i> , 2016, 67, 467-486.	12.2	192
175	Effect of reducing the nicotine content of cigarettes on cigarette smoking behavior and tobacco smoke toxicant exposure: 2-year follow up. <i>Addiction</i> , 2015, 110, 1667-1675.	3.3	33
176	Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. <i>PLoS ONE</i> , 2015, 10, e0126113.	2.5	20
177	Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking. <i>PLoS ONE</i> , 2015, 10, e0128109.	2.5	40
178	Secondhand Tobacco Smoke Exposure Among Hospitalized Nonsmokers With Coronary Heart Disease. <i>JAMA Internal Medicine</i> , 2015, 175, 133.	5.1	11
179	Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , the, 2015, 3, 131-138.	10.7	247
180	<i>UGT1A</i> and <i>UGT2B</i> Genetic Variation Alters Nicotine and Nitrosamine Glucuronidation in European and African American Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 94-104.	2.5	27

#	ARTICLE	IF	CITATIONS
181	Nicotine Dependence, Nicotine Metabolism, and the Extent of Compensation in Response to Reduced Nicotine Content Cigarettes. <i>Nicotine and Tobacco Research</i> , 2015, 17, 1167-1172.	2.6	20
182	Biochemical Estimation of Noncompliance with Smoking of Very Low Nicotine Content Cigarettes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 331-335.	2.5	23
183	Nicotine Metabolite Ratio (3-Hydroxycotinine/Cotinine) in Plasma and Urine by Different Analytical Methods and Laboratories: Implications for Clinical Implementation. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1239-1246.	2.5	65
184	Validity of self-reported adult secondhand smoke exposure. <i>Tobacco Control</i> , 2015, 24, 48-53.	3.2	40
185	Compensatory Smoking from Gradual and Immediate Reduction in Cigarette Nicotine Content. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 472-476.	2.5	52
186	Tobacco Alkaloids and Tobacco-Specific Nitrosamines in Dust from Homes of Smokeless Tobacco Users, Active Smokers, and Nontobacco Users. <i>Chemical Research in Toxicology</i> , 2015, 28, 1007-1014.	3.3	40
187	Randomized Trial of Reduced-Nicotine Standards for Cigarettes. <i>New England Journal of Medicine</i> , 2015, 373, 1340-1349.	27.0	312
188	Cardiovascular Effects of Exposure to Cigarette Smoke and Electronic Cigarettes. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1378-1391.	2.8	164
189	Different profiles of carcinogen exposure in Chinese compared with US cigarette smokers. <i>Tobacco Control</i> , 2015, 24, e258-e263.	3.2	9
190	Cigarette Smoke Toxins Deposited on Surfaces: Implications for Human Health. <i>PLoS ONE</i> , 2014, 9, e86391.	2.5	125
191	A Comparison of Nicotine Biomarkers and Smoking Patterns in Daily and Nondaily Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1264-1272.	2.5	48
192	Intake of Toxic and Carcinogenic Volatile Organic Compounds from Secondhand Smoke in Motor Vehicles. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2774-2782.	2.5	35
193	Reduced nicotine product standards for combustible tobacco: Building an empirical basis for effective regulation. <i>Preventive Medicine</i> , 2014, 68, 17-22.	3.4	61
194	Gene Variants in CYP2C19 Are Associated with Altered In Vivo Bupropion Pharmacokinetics but Not Bupropion-Assisted Smoking Cessation Outcomes. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1971-1977.	3.3	24
195	Organic Cation Transporter Variation and Response to Smoking Cessation Therapies. <i>Nicotine and Tobacco Research</i> , 2014, 16, 1638-1646.	2.6	21
196	Electronic Cigarettes. <i>Circulation</i> , 2014, 130, 1418-1436.	1.6	348
197	Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 172-176.	1.5	17
198	Emerging Nicotine Delivery Products. Implications for Public Health. <i>Annals of the American Thoracic Society</i> , 2014, 11, 231-235.	3.2	74

#	ARTICLE	IF	CITATIONS
199	Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tobacco Control, 2014, 23, 133-139.	3.2	1,324
200	E-Cigarettes. Circulation, 2014, 129, 1972-1986.	1.6	1,031
201	Children's Exposure to Secondhand and Thirdhand Smoke Carcinogens and Toxicants in Homes of Hookah Smokers. Nicotine and Tobacco Research, 2014, 16, 961-975.	2.6	57
202	Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. Addiction, 2014, 109, 1801-1810.	3.3	446
203	Nicotine and Carcinogen Exposure after Water Pipe Smoking in Hookah Bars. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1055-1066.	2.5	70
204	Multiple risk-behavior profiles of smokers with serious mental illness and motivation for change.. Health Psychology, 2014, 33, 1518-1529.	1.6	27
205	The Regulatory Challenge of Electronic Cigarettes. JAMA - Journal of the American Medical Association, 2013, 310, 685.	7.4	150
206	Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial. Addictive Behaviors, 2013, 38, 1796-1803.	3.0	33
207	Nicotelline: A Proposed Biomarker and Environmental Tracer for Particulate Matter Derived from Tobacco Smoke. Chemical Research in Toxicology, 2013, 26, 1615-1631.	3.3	37
208	<i>CHRNA5</i> genetic variants alter nicotine intake and interact with tobacco use to influence body weight in Alaska Native tobacco users. Addiction, 2013, 108, 1818-1828.	3.3	16
209	High Dose Transdermal Nicotine for Fast Metabolizers of Nicotine: A Proof of Concept Placebo-Controlled Trial. Nicotine and Tobacco Research, 2013, 15, 348-354.	2.6	27
210	Stability of the Nicotine Metabolite Ratio in Smokers of Progressively Reduced Nicotine Content Cigarettes. Nicotine and Tobacco Research, 2013, 15, 1939-1942.	2.6	24
211	Cytisine, the world's oldest smoking cessation aid. BMJ, The, 2013, 347, f5198-f5198.	6.0	41
212	Comparison of Nicotine and Carcinogen Exposure with Water Pipe and Cigarette Smoking. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 765-772.	2.5	128
213	Reducing the nicotine content to make cigarettes less addictive. Tobacco Control, 2013, 22, i14-i17.	3.2	136
214	Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. Carcinogenesis, 2013, 34, 93-101.	2.8	45
215	Racial differences in the relationship between tobacco dependence and nicotine and carcinogen exposure. Addiction, 2013, 108, 607-617.	3.3	35
216	The Ability of Plasma Cotinine to Predict Nicotine and Carcinogen Exposure is Altered by Differences in CYP2A6: the Influence of Genetics, Race, and Sex. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 708-718.	2.5	77

#	ARTICLE	IF	CITATIONS
217	Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 135-141.	1.5	55
218	Variation in Trans-3- β -Hydroxycotinine Glucuronidation Does Not Alter the Nicotine Metabolite Ratio or Nicotine Intake. <i>PLoS ONE</i> , 2013, 8, e70938.	2.5	39
219	Reproducibility of the Nicotine Metabolite Ratio in Cigarette Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1105-1114.	2.5	96
220	Bupropion for Smoking Cessation in African American Light Smokers: A Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2012, 104, 290-298.	6.3	74
221	CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 429-440.	1.5	39
222	Smoking Behavior and Exposure to Tobacco Toxicants during 6 Months of Smoking Progressively Reduced Nicotine Content Cigarettes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 761-769.	2.5	132
223	Comparison of Urine Cotinine and the Tobacco-Specific Nitrosamine Metabolite 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol (NNAL) and Their Ratio to Discriminate Active From Passive Smoking. <i>Nicotine and Tobacco Research</i> , 2011, 13, 202-208.	2.6	129
224	Nicotine Addiction: Mechanisms and Consequences. <i>International Journal of Mental Health</i> , 2011, 40, 22-38.	1.3	8
225	Impact of Smoking on Cardiovascular Events in Patients With Coronary Disease Receiving Contemporary Medical Therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in Total Mortality and Risk by Modifying Treatment Strategies in Acute Coronary Syndrome [ITD]) <i>Tj ETQq1 1,0784314 rgBT /Ove</i> 107, 145-150.	1.6	56
226	Determination of the nicotine metabolites cotinine and trans-3- β -hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: Biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 267-276.	2.3	185
227	The Threat of Menthol Cigarettes to U.S. Public Health. <i>New England Journal of Medicine</i> , 2011, 364, 2179-2181.	27.0	34
228	Nicotine, Carbon Monoxide, and Carcinogen Exposure after a Single Use of a Water Pipe. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2345-2353.	2.5	113
229	Nicotine Metabolite Ratio Predicts Smoking Topography and Carcinogen Biomarker Level. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 234-238.	2.5	101
230	Racial Differences in the Relationship Between Number of Cigarettes Smoked and Nicotine and Carcinogen Exposure. <i>Nicotine and Tobacco Research</i> , 2011, 13, 772-783.	2.6	105
231	Chronic Disease Management Approach to Treating Tobacco Addiction. <i>Archives of Internal Medicine</i> , 2011, 171, 1907.	3.8	3
232	Urine Menthol as a Biomarker of Mentholated Cigarette Smoking. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 3013-3019.	2.5	38
233	Estimation of Nicotine Dose after Low-level Exposure Using Plasma and Urine Nicotine Metabolites. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1160-1166.	2.5	46
234	Urine Cotinine Underestimates Exposure to the Tobacco-Derived Lung Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone in Passive Compared with Active Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2795-2800.	2.5	37

#	ARTICLE	IF	CITATIONS
235	Response to Letter Regarding Article, "Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease: A Randomized Trial" Circulation, 2010, 122, .	1.6	4
236	Nicotine Addiction. New England Journal of Medicine, 2010, 362, 2295-2303.	27.0	1,196
237	Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease. Circulation, 2010, 121, 221-229.	1.6	336
238	Optimal Serum Cotinine Levels for Distinguishing Cigarette Smokers and Nonsmokers Within Different Racial/Ethnic Groups in the United States Between 1999 and 2004. American Journal of Epidemiology, 2009, 169, 236-248.	3.4	544
239	Urine nicotine metabolite concentrations in relation to plasma cotinine during low-level nicotine exposure. Nicotine and Tobacco Research, 2009, 11, 954-960.	2.6	86
240	Elimination Kinetics of the Tobacco-Specific Biomarker and Lung Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 3421-3425.	2.5	131
241	Prevalence of Smoking Assessed Biochemically in an Urban Public Hospital: A Rationale for Routine Cotinine Screening. American Journal of Epidemiology, 2009, 170, 885-891.	3.4	78
242	Progressive Commercial Cigarette Yield Reduction: Biochemical Exposure and Behavioral Assessment. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 876-883.	2.5	30
243	Nicotine Chemistry, Metabolism, Kinetics and Biomarkers. Handbook of Experimental Pharmacology, 2009, , 29-60.	1.8	1,045
244	Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: A validation study. Pharmacology Biochemistry and Behavior, 2009, 92, 6-11.	2.9	200
245	Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics. Annual Review of Pharmacology and Toxicology, 2009, 49, 57-71.	9.4	664
246	Genetic and environmental influences on the ratio of 3-hydroxycotinine to cotinine in plasma and urine. Pharmacogenetics and Genomics, 2009, 19, 388-398.	1.5	72
247	Dietary supplement adverse events: Report of a one-year poison center surveillance project. Journal of Medical Toxicology, 2008, 4, 84-92.	1.5	64
248	Neurobiology of Nicotine Addiction: Implications for Smoking Cessation Treatment. American Journal of Medicine, 2008, 121, S3-S10.	1.5	267
249	Cytisine for smoking cessation: A research agenda. Drug and Alcohol Dependence, 2008, 92, 3-8.	3.2	68
250	Subpicogram per Milliliter Determination of the Tobacco-Specific Carcinogen Metabolite 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol in Human Urine Using Liquid Chromatography-Tandem Mass Spectrometry. Analytical Chemistry, 2008, 80, 8115-8121.	6.5	104
251	Rate of Nicotine Metabolism and Withdrawal Symptoms in Adolescent Light Smokers. Pediatrics, 2008, 122, e643-e647.	2.1	56
252	Urine Nicotine Metabolites and Smoking Behavior in a Multiracial/Multiethnic National Sample of Young Adults. American Journal of Epidemiology, 2007, 165, 901-910.	3.4	76

#	ARTICLE	IF	CITATIONS
253	Nicotine and Carcinogen Exposure with Smoking of Progressively Reduced Nicotine Content Cigarette. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 2479-2485.	2.5	130
254	Female sex and oral contraceptive use accelerate nicotine metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 480-488.	4.7	396
255	Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 600-608.	4.7	242
256	CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 457-467.	4.7	184
257	Nicotine intake and dose response when smoking reduced nicotine content cigarettes. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 703-714.	4.7	101
258	Within-Subject Variation of the Salivary 3HC/COT Ratio in Regular Daily Smokers: Prospects for Estimating CYP2A6 Enzyme Activity in Large-Scale Surveys of Nicotine Metabolic Rate. <i>Journal of Analytical Toxicology</i> , 2006, 30, 386-389.	2.8	60
259	Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 115-125.	1.5	68
260	Carcinogen Exposure during Short-term Switching from Regular to "Light" Cigarettes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1376-1383.	2.5	88
261	Metabolism and Disposition Kinetics of Nicotine. <i>Pharmacological Reviews</i> , 2005, 57, 79-115.	16.0	1,298
262	Pharmacotherapy for smoking cessation during pregnancy. <i>Nicotine and Tobacco Research</i> , 2004, 6, 189-202.	2.6	109
263	Mentholated Cigarette Smoking Inhibits Nicotine Metabolism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310, 1208-1215.	2.5	201
264	Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 64-72.	4.7	366
265	Clonidine for smoking cessation. <i>The Cochrane Library</i> , 2004, , CD000058.	2.8	138
266	Pharmacogenetics of Nicotine Metabolism in Twins: Methods and Procedures. <i>Twin Research and Human Genetics</i> , 2004, 7, 435-448.	1.0	2
267	Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. <i>Progress in Cardiovascular Diseases</i> , 2003, 46, 91-111.	3.1	335
268	Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 468-474.	4.7	85
269	Nicotine metabolite ratio as a predictor of cigarette consumption. <i>Nicotine and Tobacco Research</i> , 2003, 5, 621-624.	2.6	163
270	Individual differences in nicotine intake per cigarette. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 468-71.	2.5	46

#	ARTICLE	IF	CITATIONS
271	Cardiovascular Effects of Nasal and Transdermal Nicotine and Cigarette Smoking. Hypertension, 2002, 39, 1107-1112.	2.7	100
272	Biochemical verification of tobacco use and cessation. Nicotine and Tobacco Research, 2002, 4, 149-159.	2.6	1,670
273	Slower Metabolism and Reduced Intake of Nicotine From Cigarette Smoking in Chinese-Americans. Journal of the National Cancer Institute, 2002, 94, 108-115.	6.3	192
274	Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 1668-73.	2.5	58
275	Risks and Benefits of Nicotine to Aid Smoking Cessation in Pregnancy. Drug Safety, 2001, 24, 277-322.	3.2	286
276	Systemic Nicotine Exposure in Tobacco Harvesters. Archives of Environmental Health, 2001, 56, 257-263.	0.4	19
277	Simultaneous determination of mecamylamine, nicotine, and cotinine in plasma by gas chromatography-mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2000, 23, 653-661.	2.8	50
278	Nicotine Blood Levels and Subjective Craving for Cigarettes. Pharmacology Biochemistry and Behavior, 2000, 66, 553-558.	2.9	190
279	Nicotine metabolism and elimination kinetics in newborns. Clinical Pharmacology and Therapeutics, 2000, 67, 458-465.	4.7	91
280	Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. Clinical Pharmacology and Therapeutics, 2000, 67, 653-659.	4.7	61
281	Nicotine-mecamylamine interactions. Clinical Pharmacology and Therapeutics, 2000, 68, 58-66.	4.7	19
282	Non-Nicotine Pharmacotherapy for Smoking Cessation. CNS Drugs, 2000, 13, 265-285.	5.9	39
283	Carbon monoxide, cigarette smoking and CYP2E1 activity. Clinical Pharmacology and Therapeutics, 1999, 65, 154-154.	4.7	8
284	Disposition kinetics and effects of menthol. Clinical Pharmacology and Therapeutics, 1999, 66, 128-135.	4.7	77
285	The biology of nicotine dependence: From the 1988 Surgeon General's Report to the present and into the future. Nicotine and Tobacco Research, 1999, 1, 159-163.	2.6	16
286	Drug Interactions with Tobacco Smoking. Clinical Pharmacokinetics, 1999, 36, 425-438.	3.5	562
287	Disposition kinetics and effects of menthol. Clinical Pharmacology and Therapeutics, 1999, 66, 128-135.	4.7	1
288	Dose-related cardiovascular and endocrine effects of transdermal nicotine*. Clinical Pharmacology and Therapeutics, 1998, 64, 87-95.	4.7	79

#	ARTICLE	IF	CITATIONS
289	Gender differences in the pharmacology of nicotine addiction. <i>Addiction Biology</i> , 1998, 3, 383-404.	2.6	104
290	Effects of stress on circulating nicotine and cotinine levels and in vitro nicotine metabolism in the rat. <i>Psychopharmacology</i> , 1998, 137, 383-390.	3.1	28
291	Saliva cotinine levels as a function of collection method. <i>Addiction</i> , 1997, 92, 347-351.	3.3	33
292	Birthing of clinical pharmacologists*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 587-591.	4.7	9
293	Cotinine effects on nicotine metabolism*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 61, 649-654.	4.7	49
294	Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 453-463.	4.7	203
295	Saliva cotinine levels as a function of collection method. <i>Addiction</i> , 1997, 92, 347-352.	3.3	1
296	The Benefits of Stopping Smoking and the Role of Nicotine Replacement Therapy in Older Patients. <i>Drugs and Aging</i> , 1996, 9, 8-23.	2.7	44
297	Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 284-296.	4.7	35
298	The effect of liver disease on urine caffeine metabolite ratios*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 624-635.	4.7	24
299	Chronopharmacokinetics of nicotine*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 385-395.	4.7	45
300	Orthostatic Hypertension Due to Vascular Adrenergic Hypersensitivity. <i>Hypertension</i> , 1996, 28, 42-46.	2.7	24
301	Sympathomimetic effects of paraxanthine and caffeine in humans*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 684-691.	4.7	139
302	Deficient C-oxidation of nicotine*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 57, 590-594.	4.7	55
303	Is Clonidine an Effective Smoking Cessation Therapy?. <i>Drugs</i> , 1995, 50, 197-207.	10.9	60
304	Cigarette Smoking Sensitizes and Desensitizes Impedance-measured ADP-induced Platelet Aggregation in Whole Blood. <i>Thrombosis and Haemostasis</i> , 1995, 74, 730-735.	3.4	28
305	Establishing a Nicotine Threshold for Addiction – The Implications for Tobacco Regulation. <i>New England Journal of Medicine</i> , 1994, 331, 123-125.	27.0	459
306	Divergent tolerance to metabolic and cardiovascular effects of nicotine in smokers with low and high levels of cigarette consumption. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 55-64.	4.7	32

#	ARTICLE	IF	CITATIONS
307	Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clinical Pharmacology and Therapeutics, 1994, 56, 483-493.	4.7	415
308	Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Clinical Pharmacology and Therapeutics, 1993, 53, 316-323.	4.7	213
309	Pharmacokinetic-pharmacodynamic modeling of caffeine: Tolerance to pressor effects. Clinical Pharmacology and Therapeutics, 1993, 53, 6-14.	4.7	86
310	Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clinical Pharmacology and Therapeutics, 1993, 53, 529-535.	4.7	132
311	Clinical Pharmacology and Toxicology of Cocaine. Basic and Clinical Pharmacology and Toxicology, 1993, 72, 3-12.	0.0	179
312	Nicotine Replacement Therapy. Drugs, 1993, 45, 157-170.	10.9	135
313	The Use of Hemodialysis and Hemoperfusion in the Treatment of Theophylline Intoxication. Seminars in Dialysis, 1993, 6, 243-252.	1.3	9
314	Workshop on Problem-Based Learning as a Method for Teaching Clinical Pharmacology and Therapeutics in Medical School. Journal of Clinical Pharmacology, 1992, 32, 779-797.	2.0	14
315	Intravenous nicotine retards transdermal absorption of nicotine: Evidence of blood flow-limited percutaneous absorption. Clinical Pharmacology and Therapeutics, 1992, 52, 223-230.	4.7	46
316	How Toxic is Cocaine?. Novartis Foundation Symposium, 1992, 166, 125-148.	1.1	14
317	Poisoning Due to Calcium Antagonists. Drug Safety, 1991, 6, 408-430.	3.2	70
318	Pharmacodynamics of nicotine: implications for rational treatment of nicotine addiction. Addiction, 1991, 86, 495-499.	3.3	39
319	Stable isotope method for studying transdermal drug absorption: The nicotine patch. Clinical Pharmacology and Therapeutics, 1991, 50, 286-293.	4.7	77
320	Stable isotope studies of nicotine kinetics and bioavailability. Clinical Pharmacology and Therapeutics, 1991, 49, 270-277.	4.7	119
321	Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: Absence of an isotope effect in the clearance of (S)-nicotine-3,3-d ₂ in humans. Biological Mass Spectrometry, 1991, 20, 247-252.	0.5	219
322	Dose-dependency of caffeine metabolism with repeated dosing. Clinical Pharmacology and Therapeutics, 1990, 48, 277-285.	4.7	100
323	Pharmacoepidemiology of the effect of caffeine on blood pressure. Clinical Pharmacology and Therapeutics, 1990, 47, 57-60.	4.7	35
324	Poisoning Due to Class IA Antiarrhythmic Drugs Quinidine, Procainamide and Disopyramide. Drug Safety, 1990, 5, 393-420.	3.2	79

#	ARTICLE	IF	CITATIONS
325	Pharmacokinetic Considerations in Understanding Nicotine Dependence. Novartis Foundation Symposium, 1990, 152, 186-209.	1.1	37
326	Poisoning Due to Class 1B Antiarrhythmic Drugs. Medical Toxicology and Adverse Drug Experience, 1989, 4, 412-428.	0.8	27
327	Effects of passive smoking on theophylline clearance. Clinical Pharmacology and Therapeutics, 1989, 46, 399-407.	4.7	36
328	Diabetic Patients and Hepatic Drug Metabolism. Clinical Pharmacology and Therapeutics, 1989, 45, 695-694.	4.7	1
329	Synthesis of optically pure deuterium-labelled nicotine, nor nicotine and cotinine. Journal of Labelled Compounds and Radiopharmaceuticals, 1988, 25, 1117-1128.	1.0	30
330	Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum. Clinical Pharmacology and Therapeutics, 1988, 44, 23-28.	4.7	544
331	Changes in rate and pattern of caffeine metabolism after cigarette abstinence. Clinical Pharmacology and Therapeutics, 1988, 43, 488-491.	4.7	105
332	The Effect of Cigarette Smoking on Penile Erection. Journal of Urology, 1987, 138, 438-441.	0.4	94
333	Brain Phenobarbital Uptake during Prolonged Status Epilepticus. Journal of Cerebral Blood Flow and Metabolism, 1987, 7, 783-788.	4.3	18
334	Prolonged absorption with development of tolerance to toxic effects after cutaneous exposure to nicotine. Clinical Pharmacology and Therapeutics, 1987, 42, 119-120.	4.7	48
335	Determinants of nicotine intake while chewing nicotine polacrilex gum. Clinical Pharmacology and Therapeutics, 1987, 41, 467-473.	4.7	163
336	Influence of tobacco abstinence on the disposition kinetics and effects of nicotine. Clinical Pharmacology and Therapeutics, 1987, 41, 474-479.	4.7	53
337	Additive cardiovascular effects of nicotine and ethanol. Clinical Pharmacology and Therapeutics, 1986, 40, 420-424.	4.7	36
338	Mouth versus deep airways absorption of nicotine in cigarette smokers. Pharmacology Biochemistry and Behavior, 1986, 25, 1181-1184.	2.9	48
339	Reduced Tar, Nicotine, and Carbon Monoxide Exposure While Smoking Ultralow- but Not Low-Yield Cigarettes. JAMA - Journal of the American Medical Association, 1986, 256, 241.	7.4	88
340	Propranolol antagonism of phenylpropanolamine-induced hypertension. Clinical Pharmacology and Therapeutics, 1985, 37, 488-494.	4.7	45
341	Pharmacokinetic and Pharmacodynamic Considerations in Drug Therapy of Cardiac Emergencies. Clinical Pharmacokinetics, 1984, 9, 273-308.	3.5	36
342	Environmental and Drug-Induced Hyperthermia Pathophysiology, Recognition, Management. Emergency Medicine Clinics of North America, 1984, 2, 459-474.	1.2	32

#	ARTICLE	IF	CITATIONS
343	Cotinine disposition and effects. <i>Clinical Pharmacology and Therapeutics</i> , 1983, 34, 604-611.	4.7	434
344	Circadian blood nicotine concentrations during cigarette smoking. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 32, 758-764.	4.7	272
345	Lack of effect of diazepam on methadone metabolism in methadone-maintained addicts. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 31, 139-143.	4.7	41
346	Cardiovascular and Metabolic Considerations in Prolonged Cannabinoid Administration in Man. <i>Journal of Clinical Pharmacology</i> , 1981, 21, 214S-223S.	2.0	54
347	Pharmacokinetics of Drug Overdose. <i>Clinical Pharmacokinetics</i> , 1981, 6, 161-192.	3.5	56
348	Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. <i>Biomedical Applications</i> , 1981, 222, 61-70.	1.7	426
349	Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1981, 30, 183-188.	4.7	48
350	Methadoneâ€”Disulfiram Interaction During Methadone Maintenance. <i>Journal of Clinical Pharmacology</i> , 1980, 20, 506-513.	2.0	40
351	Resin hemoperfusion in ethchlorvynol overdose. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 27, 236-242.	4.7	20
352	Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 28, 115-120.	4.7	62
353	Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol: Autonomic nervous mechanisms. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 25, 440-446.	4.7	93
354	Pharmacokinetics of Haemoperfusion for Drug Overdose. <i>Clinical Pharmacokinetics</i> , 1979, 4, 329-354.	3.5	66
355	Effect of Disulfiram on Cognition, Subjective Response, and Cortical-Related Potentials in Nonalcoholic Subjects. <i>Alcoholism: Clinical and Experimental Research</i> , 1979, 3, 223-229.	2.4	19
356	Effect of disulfiram on adrenergic function. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 25, 469-475.	4.7	25
357	Diazepam kinetics in acute alcohol withdrawal. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 25, 832-836.	4.7	12
358	Clinical Pharmacokinetics of Lignocaine. <i>Clinical Pharmacokinetics</i> , 1978, 3, 177-201.	3.5	213
359	Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism Antipyrine, pentobarbital, and ethanol. <i>Clinical Pharmacology and Therapeutics</i> , 1977, 22, 259-268.	4.7	50
360	Prolonged delta-9-tetrahydrocannabinol ingestion; Effects of sympathomimetic amines and autonomic blockades. <i>Clinical Pharmacology and Therapeutics</i> , 1977, 21, 336-342.	4.7	30

#	ARTICLE	IF	CITATIONS
361	Pharmacokinetics in Patients with Cardiac Failure. Clinical Pharmacokinetics, 1976, 1, 389-405.	3.5	121
362	Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clinical Pharmacology and Therapeutics, 1975, 18, 287-297.	4.7	142
363	Lidocaine disposition kinetics in monkey and man; I. Prediction by a perfusion model. Clinical Pharmacology and Therapeutics, 1974, 16, 87-98.	4.7	203
364	Lidocaine disposition kinetics in monkey and man; II. Effects of hemorrhage and sympathomimetic drug administration. Clinical Pharmacology and Therapeutics, 1974, 16, 99-109.	4.7	106